BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20351322)

  • 21. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
    Ciccolini J; Mercier C; Dahan L; André N
    Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.
    Henon C; Huillard O; Preta LH; Blanchet B; Goldwasser F; Alexandre J
    Clin Genitourin Cancer; 2017 Jun; 15(3):e493-e495. PubMed ID: 28233698
    [No Abstract]   [Full Text] [Related]  

  • 23. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
    Miwa M; Eda H; Ura M; Ouchi KF; Keith DD; Foley LH; Ishitsuka H
    Clin Cancer Res; 1998 Feb; 4(2):493-7. PubMed ID: 9516941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
    Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
    Pharmacogenet Genomics; 2012 Jan; 22(1):58-68. PubMed ID: 22134350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
    Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
    Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?
    Moreau E; André N; Coze C; Padovani L; Mercier C; Ciccolini J
    Pediatr Blood Cancer; 2010 May; 54(5):781-2. PubMed ID: 20205259
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical pharmacology and pharmacogenetics of gemcitabine.
    Wong A; Soo RA; Yong WP; Innocenti F
    Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer.
    Jiang L; Zhang L; Shu Y; Zhang Y; Gao L; Qiu S; Zhang W; Dai W; Chen S; Huang Y; Liu Y
    J Biol Chem; 2024 Apr; 300(4):107171. PubMed ID: 38492776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
    Li H; Wang X; Wang X
    Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
    Mercier C; Raynal C; Dahan L; Ortiz A; Evrard A; Dupuis C; Blesius A; Duluc M; Franceschini F; Giacometti S; Salas S; Milano G; Favre R; Seitz JF; Ciccolini J
    Pharmacogenet Genomics; 2007 Oct; 17(10):841-4. PubMed ID: 17885621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
    Serdjebi C; Milano G; Ciccolini J
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):665-72. PubMed ID: 25495470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
    Eliopoulos N; Cournoyer D; Momparler RL
    Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
    Fanciullino R; Mercier C; Serdjebi C; Berda Y; Fina F; Ouafik L; Lacarelle B; Ciccolini J; Costello R
    Pharmacogenet Genomics; 2015 Jun; 25(6):317-21. PubMed ID: 25850965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
    Neff T; Blau CA
    Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
    Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.